Published in Proteomics on August 02, 2011
Aberrant expression of mucin core proteins and o-linked glycans associated with progression of pancreatic cancer. Clin Cancer Res (2013) 1.28
Early diagnosis of pancreatic cancer: challenges and new developments. Biomark Med (2012) 1.23
Discovery of sialyl Lewis A and Lewis X modified protein cancer biomarkers using high density antibody arrays. J Proteomics (2013) 1.10
Enhanced discrimination of malignant from benign pancreatic disease by measuring the CA 19-9 antigen on specific protein carriers. PLoS One (2011) 1.07
Diverse monoclonal antibodies against the CA 19-9 antigen show variation in binding specificity with consequences for clinical interpretation. Proteomics (2012) 0.94
Quantitative glycoproteomics analysis reveals changes in N-glycosylation level associated with pancreatic ductal adenocarcinoma. J Proteome Res (2014) 0.87
CA 19-9 and pancreatic cancer. Clin Adv Hematol Oncol (2013) 0.86
Glycoprotein disease markers and single protein-omics. Mol Cell Proteomics (2013) 0.83
Rapid characterization of candidate biomarkers for pancreatic cancer using cell microarrays (CMAs). J Proteome Res (2012) 0.83
The Marker State Space (MSS) method for classifying clinical samples. PLoS One (2013) 0.81
The detection and discovery of glycan motifs in biological samples using lectins and antibodies: new methods and opportunities. Adv Cancer Res (2015) 0.79
Definitive Characterization of CA 19-9 in Resectable Pancreatic Cancer Using a Reference Set of Serum and Plasma Specimens. PLoS One (2015) 0.78
A Systematic Review of the Diagnostic and Prognostic Value of Urinary Protein Biomarkers in Urothelial Bladder Cancer. Bladder Cancer (2016) 0.78
Proteomics analysis of bodily fluids in pancreatic cancer. Proteomics (2015) 0.78
Glycoproteins and glycoproteomics in pancreatic cancer. World J Gastroenterol (2016) 0.75
Selectin Ligands Sialyl-Lewis a and Sialyl-Lewis x in Gastrointestinal Cancers. Biology (Basel) (2017) 0.75
Connecting genetic risk to disease end points through the human blood plasma proteome. Nat Commun (2017) 0.75
High-Throughput Analysis of Plasma Hybrid Markers for Early Detection of Cancers. Proteomes (2014) 0.75
Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer (2004) 8.06
Pancreatic cancer. Annu Rev Pathol (2008) 6.96
The case for early detection. Nat Rev Cancer (2003) 6.96
Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer (2005) 6.46
Plasma lipoproteins: apolipoprotein structure and function. J Lipid Res (1984) 4.12
Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol (2006) 3.24
Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer. Ann Intern Med (1989) 3.02
The macrophage foam cell as a target for therapeutic intervention. Nat Med (2002) 2.98
Heterogeneity of apolipoprotein B: isolation of a new species from human chylomicrons. Proc Natl Acad Sci U S A (1980) 2.88
Recent progress in understanding apolipoprotein B. Circulation (1990) 2.38
Multiplexed analysis of glycan variation on native proteins captured by antibody microarrays. Nat Methods (2007) 2.06
Fucosylated haptoglobin is a novel marker for pancreatic cancer: a detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation. Int J Cancer (2006) 1.82
The prevalence and nature of glycan alterations on specific proteins in pancreatic cancer patients revealed using antibody-lectin sandwich arrays. Mol Cell Proteomics (2009) 1.77
Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer (2005) 1.34
Low-volume, high-throughput sandwich immunoassays for profiling plasma proteins in mice: identification of early-stage systemic inflammation in a mouse model of intestinal cancer. Mol Oncol (2007) 1.21
Molecular classification of neoplasms of the pancreas. Hum Pathol (2009) 1.12
Mucin glycosylation is altered by pro-inflammatory signaling in pancreatic-cancer cells. J Proteome Res (2009) 1.11
Microarrays in glycoproteomics research. Clin Lab Med (2009) 1.07
The development of an integrated platform to identify breast cancer glycoproteome changes in human serum. J Chromatogr A (2009) 1.06
Chronic pancreatitis and the differential diagnosis versus pancreatic cancer. Arch Pathol Lab Med (2009) 1.04
Antibody-lectin sandwich arrays for biomarker and glycobiology studies. Expert Rev Proteomics (2010) 1.03
IL-6 and IL-8 increase the expression of glycosyltransferases and sulfotransferases involved in the biosynthesis of sialylated and/or sulfated Lewisx epitopes in the human bronchial mucosa. Biochem J (2008) 1.00
Increased fucosylation and other carbohydrate changes in haptoglobin in ovarian cancer. Cancer Lett (1992) 0.98
Use of glycan targeting antibodies to identify cancer-associated glycoproteins in plasma of breast cancer patients. Anal Chem (2008) 0.93
Liver membrane proteome glycosylation changes in mice bearing an extra-hepatic tumor. Mol Cell Proteomics (2010) 0.93
Comparison of preoperative serum CA19-9 levels with results of diagnostic imaging modalities in patients undergoing laparotomy for suspected pancreatic or gallbladder disease. Pancreas (1994) 0.92
CA19-9 epitope a possible marker for MUC-1/Y protein. Int J Oncol (2001) 0.87
Abnormally-fucosylated serum haptoglobins in patients with inflammatory joint disease. Clin Chim Acta (1989) 0.86
Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat Med (2002) 4.54
Robot-assisted minimally invasive distal pancreatectomy is superior to the laparoscopic technique. Ann Surg (2013) 3.94
Associations between the age at diagnosis and location of colorectal cancer and the use of alcohol and tobacco: implications for screening. Arch Intern Med (2006) 3.32
Michigan Molecular Interactions (MiMI): putting the jigsaw puzzle together. Nucleic Acids Res (2006) 2.77
HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics (2005) 2.71
Meckel's diverticulum--a high-risk region for malignancy in the ileum. Insights from a population-based epidemiological study and implications in surgical management. Ann Surg (2011) 2.56
Chronic pancreatic inflammation induced by environmental tobacco smoke inhalation in rats. Am J Gastroenterol (2006) 2.51
Alcohol and smoking as risk factors in an epidemiology study of patients with chronic pancreatitis. Clin Gastroenterol Hepatol (2010) 2.46
Alcohol consumption, cigarette smoking, and the risk of recurrent acute and chronic pancreatitis. Arch Intern Med (2009) 2.23
Recent advances on the molecular mechanisms involved in pancreatic cancer progression and therapies. Pancreas (2005) 2.23
Optical markers in duodenal mucosa predict the presence of pancreatic cancer. Clin Cancer Res (2007) 2.10
Multiplexed analysis of glycan variation on native proteins captured by antibody microarrays. Nat Methods (2007) 2.06
Partial-wave microscopic spectroscopy detects subwavelength refractive index fluctuations: an application to cancer diagnosis. Opt Lett (2009) 2.04
Nanoscale cellular changes in field carcinogenesis detected by partial wave spectroscopy. Cancer Res (2009) 1.91
Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. Cancer Cell (2010) 1.88
Multicenter approach to recurrent acute and chronic pancreatitis in the United States: the North American Pancreatitis Study 2 (NAPS2). Pancreatology (2008) 1.87
Robotic-assisted major pancreatic resection and reconstruction. Arch Surg (2010) 1.82
The prevalence and nature of glycan alterations on specific proteins in pancreatic cancer patients revealed using antibody-lectin sandwich arrays. Mol Cell Proteomics (2009) 1.77
Spectroscopic microvascular blood detection from the endoscopically normal colonic mucosa: biomarker for neoplasia risk. Gastroenterology (2008) 1.73
Non-functional neuroendocrine carcinoma of the pancreas: incidence, tumor biology, and outcomes in 2,158 patients. J Gastrointest Surg (2009) 1.71
Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers. Proteomics (2003) 1.68
Elevated serum neutrophil gelatinase-associated lipocalin is an early predictor of severity and outcome in acute pancreatitis. Am J Gastroenterol (2010) 1.65
Common genetic variants in the CLDN2 and PRSS1-PRSS2 loci alter risk for alcohol-related and sporadic pancreatitis. Nat Genet (2012) 1.63
Investigation of depth-resolved nanoscale structural changes in regulated cell proliferation and chromatin decondensation. Biomed Opt Express (2013) 1.56
Antibody microarray profiling reveals individual and combined serum proteins associated with pancreatic cancer. Cancer Res (2005) 1.55
Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8⁺ T cells. Clin Cancer Res (2011) 1.54
Association between rectal optical signatures and colonic neoplasia: potential applications for screening. Cancer Res (2009) 1.53
Molecular profiling of human hepatocellular carcinoma defines mutually exclusive interferon regulation and insulin-like growth factor II overexpression. Cancer Res (2004) 1.50
Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer. Ann Surg Oncol (2010) 1.48
MUC4-expressing pancreatic adenocarcinomas show elevated levels of both T1 and T2 cytokines: potential pathobiologic implications. Am J Gastroenterol (2006) 1.48
Medullary carcinoma of the large intestine: a population based analysis. Int J Oncol (2010) 1.47
Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma. Ann Surg Oncol (2013) 1.46
A motif-based analysis of glycan array data to determine the specificities of glycan-binding proteins. Glycobiology (2009) 1.44
Transcriptional profiling of peripheral blood mononuclear cells in pancreatic cancer patients identifies novel genes with potential diagnostic utility. PLoS One (2011) 1.43
Insulin therapy and glycemic control in hospitalized patients with diabetes during enteral nutrition therapy: a randomized controlled clinical trial. Diabetes Care (2009) 1.42
Multiplex identification of gram-positive bacteria and resistance determinants directly from positive blood culture broths: evaluation of an automated microarray-based nucleic acid test. PLoS Med (2013) 1.40
Two-color, rolling-circle amplification on antibody microarrays for sensitive, multiplexed serum-protein measurements. Genome Biol (2004) 1.39
Chemoprevention strategies for pancreatic cancer. Nat Rev Gastroenterol Hepatol (2010) 1.38
Stereotactic body radiotherapy in the treatment of advanced adenocarcinoma of the pancreas. Am J Clin Oncol (2011) 1.37
Glycogene expression alterations associated with pancreatic cancer epithelial-mesenchymal transition in complementary model systems. PLoS One (2010) 1.34
Spatial-domain low-coherence quantitative phase microscopy for cancer diagnosis. Opt Lett (2010) 1.30
Distinctive serum protein profiles involving abundant proteins in lung cancer patients based upon antibody microarray analysis. BMC Cancer (2005) 1.28
Comprehensive proteome analysis of an Apc mouse model uncovers proteins associated with intestinal tumorigenesis. Cancer Prev Res (Phila) (2009) 1.27
Combined bicarbonate conductance-impairing variants in CFTR and SPINK1 variants are associated with chronic pancreatitis in patients without cystic fibrosis. Gastroenterology (2010) 1.27
Quantification of nanoscale nuclear refractive index changes during the cell cycle. J Biomed Opt (2011) 1.25
250 robotic pancreatic resections: safety and feasibility. Ann Surg (2013) 1.23
Assembly of Saccharomyces cerevisiae 60S ribosomal subunits: role of factors required for 27S pre-rRNA processing. EMBO J (2011) 1.22
A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther (2008) 1.22
Low-volume, high-throughput sandwich immunoassays for profiling plasma proteins in mice: identification of early-stage systemic inflammation in a mouse model of intestinal cancer. Mol Oncol (2007) 1.21
Development of natural protein microarrays for diagnosing cancer based on an antibody response to tumor antigens. J Proteome Res (2004) 1.19
Smoking is underrecognized as a risk factor for chronic pancreatitis. Pancreatology (2011) 1.19
Profiling bladder cancer using targeted antibody arrays. Am J Pathol (2006) 1.17
EUS-guided FNA diagnosis of pancreatic endocrine tumors: new trends identified. Gastrointest Endosc (2008) 1.17
C-stage in colon cancer: implications of carcinoembryonic antigen biomarker in staging, prognosis, and management. J Natl Cancer Inst (2011) 1.16
Nanoscale nuclear architecture for cancer diagnosis beyond pathology via spatial-domain low-coherence quantitative phase microscopy. J Biomed Opt (2011) 1.16
Differential methylation of cell-free circulating DNA among patients with pancreatic cancer versus chronic pancreatitis. Cancer (2010) 1.14
Mass spectrometric assay for analysis of haptoglobin fucosylation in pancreatic cancer. J Proteome Res (2011) 1.14
Microarrays of tumor cell derived proteins uncover a distinct pattern of prostate cancer serum immunoreactivity. Proteomics (2003) 1.13
The fine specificity of mannose-binding and galactose-binding lectins revealed using outlier motif analysis of glycan array data. Glycobiology (2011) 1.12
Integration of KRAS testing in the diagnosis of pancreatic cystic lesions: a clinical experience of 618 pancreatic cysts. Mod Pathol (2013) 1.12
Outcomes after robot-assisted pancreaticoduodenectomy for periampullary lesions. Ann Surg Oncol (2011) 1.12
Mucin glycosylation is altered by pro-inflammatory signaling in pancreatic-cancer cells. J Proteome Res (2009) 1.11
Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody: advantage of a residualizing iodine radiolabel. Breast Cancer Res Treat (2004) 1.10
BRCA1 and pancreatic cancer: pedigree findings and their causal relationships. Cancer Genet Cytogenet (2005) 1.09
A wide range of protein isoforms in serum and plasma uncovered by a quantitative intact protein analysis system. Proteomics (2005) 1.08
Optimized normalization for antibody microarrays and application to serum-protein profiling. Mol Cell Proteomics (2005) 1.08
Endoluminal delivery of radiofrequency energy to the gastroesophageal junction in uncomplicated GERD: efficacy and potential mechanism of action. Am J Gastroenterol (2002) 1.07
Microarrays in glycoproteomics research. Clin Lab Med (2009) 1.07
Enhanced discrimination of malignant from benign pancreatic disease by measuring the CA 19-9 antigen on specific protein carriers. PLoS One (2011) 1.07
Multiplex targeted proteomic assay for biomarker detection in plasma: a pancreatic cancer biomarker case study. J Proteome Res (2012) 1.06
The development of an integrated platform to identify breast cancer glycoproteome changes in human serum. J Chromatogr A (2009) 1.06
Physical and mental quality of life in chronic pancreatitis: a case-control study from the North American Pancreatitis Study 2 cohort. Pancreas (2013) 1.06
Serum immunoglobulin G fraction 4 levels in pancreatic cancer: elevations not associated with autoimmune pancreatitis. Arch Pathol Lab Med (2008) 1.05
Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. J Immunother (2007) 1.05
Association between calcium sensing receptor gene polymorphisms and chronic pancreatitis in a US population: role of serine protease inhibitor Kazal 1type and alcohol. World J Gastroenterol (2008) 1.04
Detection of the potential pancreatic cancer marker MUC4 in serum using surface-enhanced Raman scattering. Anal Chem (2011) 1.03
Unique finding of a 2009 H1N1 influenza virus-positive clinical sample suggests matrix gene sequence variation. J Clin Microbiol (2009) 1.03
Antibody-lectin sandwich arrays for biomarker and glycobiology studies. Expert Rev Proteomics (2010) 1.03
Robotic-assisted major pancreatic resection. Adv Surg (2011) 1.03
Using optical markers of nondysplastic rectal epithelial cells to identify patients with ulcerative colitis-associated neoplasia. Inflamm Bowel Dis (2011) 1.01
Value of preoperative upper endoscopy in patients undergoing laparoscopic gastric bypass. Obes Surg (2006) 0.99
Comparative effectiveness of minimally invasive and open distal pancreatectomy for ductal adenocarcinoma. JAMA Surg (2013) 0.99
An insight into statistical refractive index properties of cell internal structure via low-coherence statistical amplitude microscopy. Opt Express (2010) 0.99
Analysis of glycans on serum proteins using antibody microarrays. Methods Mol Biol (2009) 0.98
Correction of stain variations in nuclear refractive index of clinical histology specimens. J Biomed Opt (2011) 0.98